A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
OncoTargets and Therapy
The α 2 -adrenergic receptor agonist guanfacine, in its extended-release formulation (GXR), is the most recent nonstimulant medication approved in several countries for the treatment of attention-deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive pharmacotherapy to stimulants in children and adolescents. The present paper aims to review comprehensively and critically the pharmacodynamic and pharmacokinetic characteristics and the published evidence on the efficacy and safetydoi:10.2147/ott.s65735 fatcat:nkwzyzdcsvgu3mzf4vyw2yp44i